A UK medicines watchdog has reprimanded Eli Lilly over misleading advice leaflet

[Guest guest]

US drugmaker Eli Lilly criticized for misleading advice leaflet -

report

02.14.2006, 09:29 PM

http://www.forbes.com/business/feeds/afx/2006/02/14/afx2527072.html

HONG KONG (AFX) - A UK medicines watchdog has reprimanded Eli Lilly,

the US pharmaceutical group, for producing a leaflet for a patient

organization that failed to mention the potential side effects of

its drugs, the Financial Times reported.

In its online edition, the newspaper said the Medicines and

Healthcare products Regulatory Agency told Eli Lilly it must

withdraw the leaflet which gave advice to doctors that it wrote and

sponsored on behalf of the charity Diabetes UK. It must also issue a

corrective statement.

The watchdog said Eli Lilly misled patients by not making it clear

that it had written the leaflet. The leaflet only carried the

Diabetes UK logo.

It was also criticized for not highlighting the risk to patients of

hyperglycemia and diabetes when taking schizophrenia medicines

including Eli Lilly's drug Zyprexa, which generated 4.2 bln usd in

sales last year.

Eli Lilly withdrew the leaflet, saying the failure to make it clear

it had written it was an 'oversight'.

dg/dk

[Guest guest]

US drugmaker Eli Lilly criticized for misleading advice leaflet -

report

02.14.2006, 09:29 PM

http://www.forbes.com/business/feeds/afx/2006/02/14/afx2527072.html

HONG KONG (AFX) - A UK medicines watchdog has reprimanded Eli Lilly,

the US pharmaceutical group, for producing a leaflet for a patient

organization that failed to mention the potential side effects of

its drugs, the Financial Times reported.

In its online edition, the newspaper said the Medicines and

Healthcare products Regulatory Agency told Eli Lilly it must

withdraw the leaflet which gave advice to doctors that it wrote and

sponsored on behalf of the charity Diabetes UK. It must also issue a

corrective statement.

The watchdog said Eli Lilly misled patients by not making it clear

that it had written the leaflet. The leaflet only carried the

Diabetes UK logo.

It was also criticized for not highlighting the risk to patients of

hyperglycemia and diabetes when taking schizophrenia medicines

including Eli Lilly's drug Zyprexa, which generated 4.2 bln usd in

sales last year.

Eli Lilly withdrew the leaflet, saying the failure to make it clear

it had written it was an 'oversight'.

dg/dk

[Guest guest]

US drugmaker Eli Lilly criticized for misleading advice leaflet -

report

02.14.2006, 09:29 PM

http://www.forbes.com/business/feeds/afx/2006/02/14/afx2527072.html

HONG KONG (AFX) - A UK medicines watchdog has reprimanded Eli Lilly,

the US pharmaceutical group, for producing a leaflet for a patient

organization that failed to mention the potential side effects of

its drugs, the Financial Times reported.

In its online edition, the newspaper said the Medicines and

Healthcare products Regulatory Agency told Eli Lilly it must

withdraw the leaflet which gave advice to doctors that it wrote and

sponsored on behalf of the charity Diabetes UK. It must also issue a

corrective statement.

The watchdog said Eli Lilly misled patients by not making it clear

that it had written the leaflet. The leaflet only carried the

Diabetes UK logo.

It was also criticized for not highlighting the risk to patients of

hyperglycemia and diabetes when taking schizophrenia medicines

including Eli Lilly's drug Zyprexa, which generated 4.2 bln usd in

sales last year.

Eli Lilly withdrew the leaflet, saying the failure to make it clear

it had written it was an 'oversight'.

dg/dk

[Guest guest]

US drugmaker Eli Lilly criticized for misleading advice leaflet -

report

02.14.2006, 09:29 PM

http://www.forbes.com/business/feeds/afx/2006/02/14/afx2527072.html

HONG KONG (AFX) - A UK medicines watchdog has reprimanded Eli Lilly,

the US pharmaceutical group, for producing a leaflet for a patient

organization that failed to mention the potential side effects of

its drugs, the Financial Times reported.

In its online edition, the newspaper said the Medicines and

Healthcare products Regulatory Agency told Eli Lilly it must

withdraw the leaflet which gave advice to doctors that it wrote and

sponsored on behalf of the charity Diabetes UK. It must also issue a

corrective statement.

The watchdog said Eli Lilly misled patients by not making it clear

that it had written the leaflet. The leaflet only carried the

Diabetes UK logo.

It was also criticized for not highlighting the risk to patients of

hyperglycemia and diabetes when taking schizophrenia medicines

including Eli Lilly's drug Zyprexa, which generated 4.2 bln usd in

sales last year.

Eli Lilly withdrew the leaflet, saying the failure to make it clear

it had written it was an 'oversight'.

dg/dk